69 Best Biotech Startups to Watch in 2024
How do we build this list? TLDR: Using math and experts.
Tracking:
Last update to the database: April 9, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
Sign up to Seedtable Intel to access the entire database
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Drug discovery platform. |
$32M · Series A | Wendel Growth, Bpifrance, Elaia | 51 to 100 | Biotech | B2B | Paris, France | •••••••••••@aqemia.com | |
Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. |
$139M · Series B | Nextech Invest, EQT Life Sciences, Andera Partners | 11 to 50 | Health Tech, Biotech, Deep Tech | B2B | Munich, Germany | •••••••••••@tubulis.com | |
Developer of a universal AI foundation model for biology. |
$35M · Seed | Frst, Bpifrance, Sofinnova Partners | 1 to 10 | AI, Biotech | B2B, SaaS | Paris, France | •••••••••••@bioptimus.com | |
Eco-friendly liquid-liquid direct lithium extraction (DLE) process developer. |
$27M · Series B | Celeste Management, Sociedad Quimica Y Minera (SQM), Bpifrance | 11 to 50 | Climate Tech & Green Tech, Biotech | B2B | Paris, France | •••••••••••@adionics.com | |
AI vaccine algorithm developer. |
$11M · Series A | Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures | 1 to 10 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@baseimmune.co.uk | |
Biomedical research discovery tool. |
$60M · Series B | ICONIQ Growth, Index Ventures, Pentech Ventures | 51 to 100 | Health Tech, AI, Biotech, Pharma | B2B, SaaS | London, UK | •••••••••••@causaly.com | |
Animal-free egg protein producer for food manufacturers. |
$28M · Series A | EIT Food, Agronomics, Tesi | 11 to 50 | Foodtech, Biotech | B2B | Helsinki, Finland | •••••••••••@onego.bio | |
Oophthalmic gene therapy company to treat blinding retinal illnesses. |
$120M · Series A | Syncona Partners LLP | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@beacontx.com | ||
Portfolio of pharmaceutical research and discovery. |
$33M · Series C | Patient Square Capital, Rock Springs Capital, M&G Investments | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@apollotherapeutics.com | ||
Gene-editing platform. |
$30M · Series B | Sanofi Ventures, Khosla Ventures, Bpifrance | 11 to 50 | Health Tech, Biotech | Paris, France | •••••••••••@eligo.bio | ||
Developer of therapies for inflammatory and fibrotic diseases. |
$81M · Series A | Sarsia, p53, Forbion Capital Partners | 11 to 50 | Biotech, Pharma | Oslo, Norway | •••••••••••@callunapharma.com | ||
AI platform to map the human immune system. |
$14M · Series A | Life Extension Ventures, Molten Ventures | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@imubiosciences.com | ||
Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies. |
$8M · Series A | Mercia Asset Management | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@mipdiscovery.com | ||
Cancer survivors data analysis platform. |
$16M · Seed | Hitachi Ventures, Life Extension Ventures, Sofinnova Partners | 11 to 50 | Biotech, Data and Analytics | B2B, SaaS | Paris, France | •••••••••••@cure51.com | |
Biosensors developer to combat chronic kidney disease. |
$2M · Pre Seed | Bpifrance, Kima Ventures, Cenitz | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@metyos.com | ||
Developer of sustainable plant-based pigments. |
$3M · Seed | PDS Ventures, Circular Innovation Fund, L'Oreal | 1 to 10 | Biotech, Manufacturing | B2C | London, UK | •••••••••••@sparxell.com | |
Mnemo Therapeutics specializes in biotechnology and life science. |
$89M · Series A | Sofinnova Partners | 101 to 250 | Health Tech, Biotech | B2B | Paris, France | •••••••••••@mnemo-tx.com | |
Fully-automated cell manufacturing. |
$19M · Series A | Buckley Ventures, Wing Venture Capital, IQ Capital Partners | 11 to 50 | Biotech, Machine Learning | B2B | London, UK | •••••••••••@mytos.bio | |
Oral macrocycle drug discovery platform. |
$28M · Seed | Novo A/S, Forbion Capital Partners | 1 to 10 | Health Tech, Biotech | B2B | Copenhagen, Denmark | •••••••••••@orbismedicines.com | |
SparingVision is a biotechnology company focused development of genomic medicines for the treatment of blinding inherited retinal diseases. |
$52M · Series A | Ysios Capital | 1 to 10 | Health Tech, Biotech, Deep Tech | B2B | Paris, France | •••••••••••@sparingvision.com | |
Preclinical stage treatment for geographic atrophy. |
$78M · Series A | Forbion Capital Partners, Gimv | 1 to 10 | Biotech | London, UK | •••••••••••@complementtx.com | ||
Discovery and development platform of superior microbial bioproducts. |
$6M · Series A | Pymwymic, Clean Growth Fund | 1 to 10 | Biotech | London, UK | •••••••••••@fungialert.com | ||
Immunotherapies developer for cancer patient. |
$2M · Seed | Fournier-Majoie, Meusinvest (Noshaq), xista science ventures | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@hephaistos-pharma.fr | ||
Polyhydroxyalkanoates (PHA) producer. |
$15M · Seed | NV NOM, Invest-NL | 1 to 10 | Biotech | Amsterdam, Netherlands | •••••••••••@paquesbiomaterials.nl | ||
Neuroscience-driven AI platform. |
$2M · Seed | Rockmount Capital, UCL Technology Fund, Moonfire Ventures | 11 to 50 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@stanhopeai.com | |
Advanced allosteric modulator therapeutics developer for neurological disorders. |
$63M · Series A | Xontogeny, Perceptive Advisors, Acorn Bioventures | 1 to 10 | Health Tech, Biotech | Geneva, Switzerland | •••••••••••@neurosterix.com | ||
Innovative immunotherapies developer for cancer patients. |
$51M | Forbion Capital Partners, Vesalius Biocapital Partners, Bayern Kapital | 11 to 50 | Health Tech, Biotech, Manufacturing | B2B | Munich, Germany | •••••••••••@catalym.com | |
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins. |
$50M · Series A | General Catalyst, Khosla Ventures | 1 to 10 | Health Tech, AI, Biotech, Data and Analytics | B2B | London, UK | •••••••••••@charmtx.com | |
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases. |
$46M | Bioqube Ventures | 11 to 50 | Health Tech, Biotech | B2B | Paris, France | •••••••••••@egle-tx.com | |
Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases. |
$3M · Series F | The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Paris, France | •••••••••••@enterome.com | |
Eyevensys creates ophthalmic therapeutic bio factories to sustainably treat major eye diseases. |
$30M · Series B | Pureos Bioventures, Karista | 11 to 50 | Health Tech, Hardware, Biotech, Manufacturing | B2B | Paris, France | •••••••••••@eyevensys.com | |
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. |
$25M | Kindred Capital, Atomico | 51 to 100 | Health Tech, AI, Biotech, Deep Tech, Machine Learning, Robotics, Manufacturing | B2B | London, UK | •••••••••••@labgeni.us | |
Clinical trials platform. |
$18M · Series A | Valar Ventures, Seedcamp, Atomico | 11 to 50 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@lindushealth.com | |
Developer of prophylactic vaccine against Group B Streptococcus. |
$57M · Series C | EQT Partners, Novo A/S, OrbiMed | 1 to 10 | Health Tech, Biotech | B2B | Copenhagen, Denmark | •••••••••••@minervax.com | |
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. |
$30M · Series A | Kindred Capital, Octopus Ventures, Amadeus Capital | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@oribiotech.com | |
Cancer treatment predictor software. |
$14M · Series A | Hoxton Ventures, Octopus Ventures, Fly Ventures | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@pearbio.com | |
Quell Therapeutics is a cell therapy company |
$45M · Series A | AlbionVC, Point72 Ventures | 101 to 250 | Health Tech, Edtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@quell-tx.com | |
ReViral is a biotechnology company that develops and offers antiviral therapies for patients. |
$44M · Series C | Novo A/S, Andera Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@reviral.co.uk | |
Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits. |
$28M · Series B | Future Planet Capital | 11 to 50 | Agritech, Biotech, Deep Tech, Manufacturing | B2B | London, UK | •••••••••••@tropicbioscience.com | |
Fermentation process to produce protein from animals. |
$5M · Seed | Voyager Ventures, Revent, World Fund | 1 to 10 | Foodtech, Biotech | B2C | Amsterdam, Netherlands | •••••••••••@farmless.com | |
Precision software for eye surgery. |
$8M · Seed | Redalpine | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@hypervisionsurgical.com | ||
Gene therapies for inherited retinal disorders. |
$65M · Series A | Forbion Capital Partners | 1 to 10 | Biotech | Milan, Italy | •••••••••••@aavantgardebio.com | ||
Precision therapeutics discovery platform. |
$6M · Seed | Hoxton Ventures | 11 to 50 | Biotech | B2B | London, UK | •••••••••••@multiomic.uk | |
Automated bioprocessing system for the production of cell and gene therapies. |
$18M · Seed | AdBio Partners | 11 to 50 | Biotech | Paris, France | •••••••••••@astraveus.com | ||
Platform to automate the clinical studies process. |
$12M · Series A | Playfair, Delin Ventures, 11.2 Capital | 11 to 50 | Health Tech, Biotech | B2B | London, UK | •••••••••••@umed.io | |
Patent-protected anti-inflammatory painkiller. |
$6M · Series A | ITV AdVentures | 1 to 10 | Biotech, Pharma | B2C | London, UK | •••••••••••@flarin.co.uk | |
User-owned genomics database platform. |
$20M · Series A | GEM Digital | 1 to 10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@genomes.io | |
Medical devices for a transvascular treatment of pulmonary hypertension. |
$14M · Series A | Sofinnova Partners, Asabys Partners | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@gradientdenervation.com | ||
Gene silencing platform for the creation of programmable, allogeneic cell therapies. |
$16M · Seed | Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@laverocktx.com | ||
3D human lung model developer. |
$2M · Seed | Pioneer Group, Mercia Asset Management, Midlands Engine Investment Fund | 11 to 50 | Biotech, Deep Tech | London, UK | •••••••••••@immuone.com | ||
Breast milk producer from cell-cultured mammary glands. |
$3M · Pre Seed | Heartcore, Kima Ventures, Kost Capital | 1 to 10 | Biotech, FamilyTech & Parenting | B2C | Paris, France | •••••••••••@numi.life | |
AI platform for radiology diagnostics. |
$5M · Seed | xdeck, 10x Founders | 11 to 50 | Health Tech, Biotech | Munich, Germany | •••••••••••@floy.com | ||
Biomanufacturer of complex molecules. |
$4M · Seed | Meusinvest (Noshaq) | 1 to 10 | Biotech, Manufacturing | Paris, France | •••••••••••@samabriva.com | ||
Therapeutic protein developer for chronic neuropathic pain. |
$24M · Series A | Medical Incubator Japan, Borean Innovation, Novo A/S | 1 to 10 | Health Tech, Biotech | Copenhagen, Denmark | •••••••••••@hobatherapeutics.com | ||
AI-powered drug testing platform. |
$1M · Pre Seed | Seedcamp, Episode 1 | 1 to 10 | AI, Biotech | London, UK | •••••••••••@sablebio.com | ||
Viral vector-based cancer vaccines developer. |
$82M · Series C | Bpifrance, 5AM Ventures, Abingworth | 1 to 10 | Health Tech, Biotech | B2C | Basel, Switzerland | •••••••••••@nouscom.com | |
Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. |
$17M · Seed | AlbionVC, Boxer Capital, Syncona Partners LLP | 101 to 250 | Health Tech, Biotech | B2B | London, UK | •••••••••••@achillestx.com | |
Early detection of Alzheimer's disease (AD) technology. |
$5M · Series A | EIC Accelerator, WA4STEAM, Ship2B | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Barcelona, Spain | •••••••••••@admit-therapeutics.com | |
Developer of bio-fabricated silk protein materials. |
$27M · Series C | Novo A/S | 11 to 50 | Health Tech, Biotech, Manufacturing | B2B | Munich, Germany | •••••••••••@amsilk.com | |
Producer of gut health binding proteins. |
$32M · Series A | Bill & Melinda Gates Foundation, Novo A/S | 1 to 10 | Biotech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@bactolife.com | |
Daye is a gynecological health company that creates products and services for vaginal treatment. |
$5M · Seed | Index Ventures, Khosla Ventures, Kindred Capital | 11 to 50 | Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis | B2C | London, UK | •••••••••••@yourdaye.com | |
Bio alternative to fossil-based and energy–intensive chemical production. |
$22M · Series B | Sofinnova Partners, SEB Venture Capital, Industrifonden | 51 to 100 | Health Tech, Biotech | B2B | Stockholm, Sweden | •••••••••••@enginzyme.com | |
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases. |
$6M · Series A | Fountain Healthcare Partners | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Paris, France | •••••••••••@ermium.com | |
Treatments for genetic bleeding disorders. |
$135M · Series B | Novo A/S, HealthCap | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@hemab.com | |
Quantum simulation platform for drug discovery. |
$2M · Seed | Ascension Ventures, ACF Investors | 1 to 10 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@kuano.ai | |
Manufacturer of medicines to protect from the threat of respiratory viruses |
$47M | GV, SoftBank Group | 11 to 50 | Health Tech, Biotech, Deep Tech | B2B | Amsterdam, Netherlands | •••••••••••@leydenlabs.com | |
Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors. |
$6M · Seed | Sofinnova Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@myricxpharma.com | |
nextProtein develops a new large-scale technology that produces a sustainable source of protein. |
$11M · Series A | Blue Oceans Partners | 11 to 50 | Climate Tech & Green Tech, Agritech, Foodtech, Biotech, Manufacturing | B2B | Paris, France | •••••••••••@nextprotein.co | |
Innovative therapeutic drugs to treat inflammatory, metabolic and liver diseases. |
$27M · Series A | Sofinnova Partners, Novo A/S, Forbion Capital Partners | 11 to 50 | Health Tech, Biotech | B2B | Amsterdam, Netherlands | •••••••••••@northseatherapeutics.com |
Sign up to access our full database
Enter your email and get access to 17,000+ technology companies you can partner with – 937 in Biotech.
- Manufacturing... (2495)
- Fintech... (2406)
- Health Tech... (2402)
- Ecommerce... (1779)
- Mobile... (1596)
- Data and Analytics... (1490)
- AI... (1481)
- Business Intell...... (1466)
- Hardware... (1237)
- Climate Tech & ...... (1040)
- Energy & Nuclear... (956)
- Biotech... (938)
- Sales and Marke...... (928)
- Mobility & Tran...... (921)
- Foodtech... (910)
- Proptech & Real...... (892)
- Deep Tech... (806)
- Media and Enter...... (788)
- Crypto & web3... (681)
- Edtech... (651)
- CPG & Consumer ...... (624)
- Privacy and Sec...... (517)
- Developer Tools... (492)
- Gaming... (484)
- Payments... (474)
- Machine Learning... (473)
- Communications... (463)
- Hiring and Recr...... (454)
- Fashion... (425)
- Community & Lif...... (410)
- Agritech... (387)
- Travel Tech... (383)
- Adtech... (369)
- Sportstech... (350)
- Legal Tech... (349)
- Consumer Social... (294)
- Cybersecurity... (283)
- Video... (281)
- Pharma... (272)
- Supply Chain & ...... (270)
- Robotics... (269)
- Creative Tools... (258)
- Productivity Tools... (250)
- Enterprise Soft...... (248)
- Insuretech... (224)
- CRM... (211)
- Future of Work... (211)
- AR / VR... (207)
- Internet of Things... (204)
- Music and Audio... (200)
- Fitness... (190)
- Cloud... (177)
- Service Industry... (160)
- Food Delivery... (134)
- Investing... (128)
- Space Tech... (124)
- Wearables... (112)
- Identity Manage...... (91)
- Navigation and ...... (83)
- Electric Vehicles... (82)
- Publishing... (77)
- ElderTech... (75)
- Personal Finance... (67)
- Messaging... (63)
- Semiconductor... (62)
- Govtech... (62)
- Art... (62)
- Drones... (61)
- Open Source... (55)
- IT Management... (50)
- Pet Tech... (49)
- Quantum Computing... (44)
- FamilyTech & Pa...... (43)
- Esports... (34)
- Genetics... (29)